Genes, BRCA2

• 

  Subject Areas on Research

  • A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. 
  • Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. 
  • Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation. 
  • An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. 
  • Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. 
  • Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes. 
  • Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. 
  • Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. 
  • BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. 
  • BRCA mutations in women with ductal carcinoma in situ. 
  • BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. 
  • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. 
  • Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate. 
  • Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. 
  • Characterization of BRCA1 and BRCA2 mutations in a large United States sample. 
  • Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study. 
  • Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). 
  • Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. 
  • Coping with genetic testing for breast cancer susceptibility. 
  • DNA patents and diagnostics: not a pretty picture. 
  • Does a BRCA mutation plus tamoxifen equal hysterectomy? 
  • Ductal carcinoma in situ in BRCA mutation carriers. 
  • Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. 
  • Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. 
  • Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes. 
  • Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. 
  • Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore. 
  • Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. 
  • Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics. 
  • Genomic tests for ovarian cancer detection and management. 
  • Hereditary ovarian cancer in Ashkenazi Jews. 
  • Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. 
  • High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. 
  • Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. 
  • Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. 
  • Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations. 
  • Interest in BRCA1/2 testing in a primary care population. 
  • Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. 
  • Male breast cancer during treatment with leuprolide for prostate cancer. 
  • Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. 
  • Modeling genetic risk of breast cancer. 
  • Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys. 
  • Oophorectomy in carriers of BRCA mutations. 
  • Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. 
  • Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. 
  • Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. 
  • Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. 
  • Pre-counseling education materials for BRCA testing: does tailoring make a difference? 
  • Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. 
  • Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. 
  • Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. 
  • Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. 
  • Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. 
  • Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. 
  • Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. 
  • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. 
  • Role of genetic polymorphisms and ovarian cancer susceptibility. 
  • Slip-sliding away: serial changes and homoplasy in repeat number in the Drosophila yakuba homolog of human cancer susceptibility gene BRCA2. 
  • Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. 
  • Surgeons' Perspectives of Contralateral Prophylactic Mastectomy. 
  • Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? 
  • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. 
  • The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. 
  • Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. 
  • Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. 
  • Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. 
  • Validity of models for predicting BRCA1 and BRCA2 mutations. 
  • Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. 
  • Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology